Impact of Bone Marrow Segmentation on Dose Estimates In High‑ Vs Low‑ Disease Burden Patients Treated with 177lu‑PSMA‑617
Bone marrow (BM) is an organ-at-risk for 177Lu-PSMA radiopharmaceutical therapy, but estimating the absorbed dose (AD) is challenged by the segmentation of disseminated BM. In this work, we evaluated the impact of two segmentation approaches on AD estimates i...
Proffered Program · Radiopharmaceuticals, Theranostics, and Nuclear Medicine